[go: up one dir, main page]

NO20013381D0 - 2-oksybenzoksazinonderivater for behandling av fedme - Google Patents

2-oksybenzoksazinonderivater for behandling av fedme

Info

Publication number
NO20013381D0
NO20013381D0 NO20013381A NO20013381A NO20013381D0 NO 20013381 D0 NO20013381 D0 NO 20013381D0 NO 20013381 A NO20013381 A NO 20013381A NO 20013381 A NO20013381 A NO 20013381A NO 20013381 D0 NO20013381 D0 NO 20013381D0
Authority
NO
Norway
Prior art keywords
oxybenzoxazinone
obesity
derivatives
treatment
oxybenzoxazinone derivatives
Prior art date
Application number
NO20013381A
Other languages
English (en)
Other versions
NO333922B1 (no
NO20013381L (no
Inventor
Harold Francis Hodson
Robert Downham
Timothy John Mitchell
Beverley Jane Carr
Christopher Robert Dunk
Richard Michael John Palmer
Original Assignee
Alizyme Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9900413.7A external-priority patent/GB9900413D0/en
Priority claimed from GBGB9917294.2A external-priority patent/GB9917294D0/en
Application filed by Alizyme Therapeutics Ltd filed Critical Alizyme Therapeutics Ltd
Publication of NO20013381D0 publication Critical patent/NO20013381D0/no
Publication of NO20013381L publication Critical patent/NO20013381L/no
Publication of NO333922B1 publication Critical patent/NO333922B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO20013381A 1999-01-08 2001-07-06 2-oksybenzoksazinonderivater, fremgangsmåte for fremstilling, anvendelse derav for fremstilling av et medikament for behandling av fedme samt farmasøytisk preparat og matprodukt omfattende forbindelsen NO333922B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9900413.7A GB9900413D0 (en) 1999-01-08 1999-01-08 Inhibitors
GBGB9917294.2A GB9917294D0 (en) 1999-07-22 1999-07-22 Inhibitors
PCT/GB2000/000032 WO2000040247A1 (en) 1999-01-08 2000-01-06 2-oxy-benzoxazinone derivatives for the treatment of obesity

Publications (3)

Publication Number Publication Date
NO20013381D0 true NO20013381D0 (no) 2001-07-06
NO20013381L NO20013381L (no) 2001-09-07
NO333922B1 NO333922B1 (no) 2013-10-21

Family

ID=26314965

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013381A NO333922B1 (no) 1999-01-08 2001-07-06 2-oksybenzoksazinonderivater, fremgangsmåte for fremstilling, anvendelse derav for fremstilling av et medikament for behandling av fedme samt farmasøytisk preparat og matprodukt omfattende forbindelsen

Country Status (24)

Country Link
US (4) US6624161B2 (no)
EP (1) EP1143977B3 (no)
JP (1) JP3822439B2 (no)
KR (1) KR100678998B1 (no)
CN (2) CN1915981B (no)
AR (1) AR022204A1 (no)
AT (1) ATE293447T1 (no)
AU (1) AU765147C (no)
CA (1) CA2359819C (no)
CH (1) CH1143977H1 (no)
DE (1) DE60019555C5 (no)
DK (1) DK1143977T3 (no)
ES (1) ES2240052T7 (no)
HK (1) HK1047588B (no)
HU (1) HUP0105003A3 (no)
MX (1) MXPA01006921A (no)
MY (1) MY122578A (no)
NO (1) NO333922B1 (no)
NZ (1) NZ512740A (no)
PL (1) PL207383B1 (no)
PT (1) PT1143977E (no)
RU (1) RU2245331C2 (no)
SI (1) SI1143977T1 (no)
WO (1) WO2000040247A1 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022204A1 (es) * 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
GB0001572D0 (en) * 2000-01-24 2000-03-15 Alizyme Therapeutics Ltd Inhibitors
US6504028B2 (en) * 2000-07-11 2003-01-07 The Procter & Gamble Co. Process for preparing benzoxazin-4-one polymer conjugates
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
RU2356550C2 (ru) 2001-01-26 2009-05-27 Шеринг Корпорейшн Комбинации активатора (активаторов) рецептора, активируемого пролифератором пероксисом (рапп), и ингибитора (ингибиторов) всасывания стерина и лечение заболеваний сосудов
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CZ305202B6 (cs) 2001-01-26 2015-06-10 Merck Sharp & Dohme Corp. Farmaceutický prostředek
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
WO2003013571A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
JP2005527469A (ja) * 2001-08-30 2005-09-15 アリザイム セラピューティクス リミティッド リパーゼ阻害活性をもったチエノ−（１，３）−オキサジン−４−オン類
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AU2002336609B2 (en) 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
KR20040068316A (ko) * 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 판크레아 리파제 저해제 화합물, 그의 합성방법 및사용방법
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CA2530634A1 (en) * 2003-06-12 2004-12-23 Menachem Rubinstein Methods of treating obesity and related disorders using tellurium and selenium compounds
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
EP1807063A2 (en) 2004-10-25 2007-07-18 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
WO2006116773A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of California Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders
WO2006132440A1 (ja) 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited 固形製剤
JP2010254623A (ja) * 2009-04-24 2010-11-11 Takeda Chem Ind Ltd ベンゾオキサジノン化合物の結晶
EP2575768B1 (en) 2010-05-24 2017-12-13 Swedish Oat Fiber AB Aqueous dispersion comprising galactolipids and method for production thereof
NL2009995C2 (en) * 2011-12-23 2013-09-18 Norgine Bv Compositions.
WO2013092786A1 (en) 2011-12-23 2013-06-27 Norgine B.V. Compositions comprising cetilistat
DE202012104963U1 (de) 2012-12-19 2013-01-14 Norgine B.V. Cetilistat aufweisende Zusammensetzungen
CN103936687B (zh) * 2014-03-24 2016-03-30 重庆东得医药科技有限公司 一种制备西替利司他的方法
CN104374836A (zh) * 2014-09-19 2015-02-25 安徽安科生物工程（集团）股份有限公司 西替利司他及有关杂质的hplc测定方法
CN105622538B (zh) * 2014-10-27 2019-02-01 中国医学科学院药物研究所 一锅法高收率制备新利司他
CN104341370B (zh) * 2014-11-11 2017-02-22 山东创新药物研发有限公司 一种西替利司他的制备方法
CN105669585A (zh) * 2016-01-06 2016-06-15 北京修正创新药物研究院有限公司 一种新利司他的制备方法
CN105566164A (zh) * 2016-01-06 2016-05-11 北京修正创新药物研究院有限公司 一种新利司他杂质的制备方法
WO2018011676A1 (en) * 2016-07-11 2018-01-18 Symed Labs Limited Novel processes for the preparation of 2-oxy-benzoxazinone derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE246996C (no)
US4657893A (en) 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4745116A (en) 1985-06-25 1988-05-17 Syntex (U.S.A.) Inc. 2-oxy-4H-3,1-benzoxazin-4-ones and related compounds and pharmaceutical use
US4665070A (en) * 1985-06-25 1987-05-12 Syntex (U.S.A.) Inc. 2-oxy-4H-3,1-benzoxazin-4-ones and pharmaceutical use
DD246996A1 (de) * 1986-02-26 1987-06-24 Univ Leipzig Verfahren zur herstellung von gegebenenfalls substituierten 2-alkoxy- bzw. 2-aroxy-3,1-benzoxazin-4-onen
CA1309556C (en) * 1987-06-09 1992-10-27 Masayuki Kokubo 4h-3,1-benzoxazin-4-one compounds and pharmaceutical composition thereoffor the inhibition of serine proteases
US5652237A (en) 1994-09-09 1997-07-29 Warner-Lambert Company 2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes
US5985872A (en) * 1995-05-24 1999-11-16 G.D. Searle & Co. 2-amino-benzoxazinones for the treatment of viral infections
US5776756A (en) * 1995-08-31 1998-07-07 Toyo Hakko Co., Ltd. Fermentation compositions having superoxide dismutating activity and an antihypertensive agent for treatment of constipation each having the superoxide dismutating activity
US6136566A (en) * 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6139833A (en) * 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
US6207371B1 (en) * 1996-10-04 2001-03-27 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6130214A (en) * 1997-10-27 2000-10-10 Dr. Reddy's Research Foundation Benzothiazin and benzoxazin derivatives; their preparation and uses
US6080576A (en) * 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
AR022204A1 (es) * 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.

Also Published As

Publication number Publication date
HUP0105003A2 (en) 2002-06-29
ATE293447T1 (de) 2005-05-15
SI1143977T1 (no) 2005-08-31
US8877750B2 (en) 2014-11-04
EP1143977B1 (en) 2005-04-20
ES2240052T3 (es) 2005-10-16
US6624161B2 (en) 2003-09-23
US20030027821A1 (en) 2003-02-06
CN1915981B (zh) 2011-09-28
KR100678998B1 (ko) 2007-02-07
DE60019555T2 (de) 2006-02-23
HUP0105003A3 (en) 2004-11-29
DE60019555D1 (de) 2005-05-25
JP3822439B2 (ja) 2006-09-20
CH1143977H1 (fr) 2007-02-15
HK1047588B (zh) 2007-08-24
US7858617B2 (en) 2010-12-28
EP1143977B3 (en) 2012-10-24
CA2359819A1 (en) 2000-07-13
AU765147C (en) 2007-05-31
AU765147B2 (en) 2003-09-11
AU1884600A (en) 2000-07-24
JP2002534388A (ja) 2002-10-15
CN1915981A (zh) 2007-02-21
CN1359378A (zh) 2002-07-17
WO2000040247A8 (en) 2001-02-15
HK1047588A1 (en) 2003-04-24
US20110065697A1 (en) 2011-03-17
WO2000040247A9 (en) 2002-10-24
NO333922B1 (no) 2013-10-21
NZ512740A (en) 2003-10-31
DE60019555C5 (de) 2009-07-09
RU2245331C2 (ru) 2005-01-27
EP1143977A1 (en) 2001-10-17
CN1315813C (zh) 2007-05-16
KR20020000542A (ko) 2002-01-05
US7825113B2 (en) 2010-11-02
MXPA01006921A (es) 2003-06-04
NO20013381L (no) 2001-09-07
DK1143977T3 (da) 2005-08-15
PT1143977E (pt) 2005-08-31
US20030195206A1 (en) 2003-10-16
AR022204A1 (es) 2002-09-04
MY122578A (en) 2006-04-29
PL207383B1 (pl) 2010-12-31
US20080161301A1 (en) 2008-07-03
HK1103928A1 (en) 2007-12-28
CA2359819C (en) 2008-08-12
WO2000040247A1 (en) 2000-07-13
ES2240052T7 (es) 2013-02-14

Similar Documents

Publication Publication Date Title
NO20013380D0 (no) 2-aminobenzoksazinonderivater for behandling av fedme
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
NO20014379L (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
NO986052D0 (no) Antikonvulsive derivater for behandling av fedme
NO20021400D0 (no) Terapeutiske konazolinderivater
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
SI1231920T1 (sl) Uporaba epinastina za zdravljenje alergijskega renitisa/konjuktivitisa
NO20020358D0 (no) Anvendelse av etodolac for behandling av kreft
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
NO20020784L (no) Medikament for behandling av brudd
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
NO20014477L (no) Behandling av osteoartritis
NO20014026D0 (no) Krampestillende derivater til behandling av betydelig skjelving
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
NO20014476L (no) Behandling av hiatial hernia
NO996166L (no) FremgangsmÕte for behandling av avluter
IT1311582B1 (it) Ortesi ortopedica per il trattamento di epicondiliti.
NO20014093D0 (no) Behandling av infertilitet

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees